Irritable Bowel Syndrome Forecast in 12 Major Markets 2017-2027 Split by Gender and 5-Year Age Cohort

Dublin, March 27, 2017 -- Research and Markets has announced the addition of the "Irritable Bowel Syndrome Forecast in 12 Major Markets 2017-2027" report to their offering.

Irritable Bowel Syndrome (IBS) is a functional bowel disorder which incorporates a group of symptoms but includes abdominal pain and disturbed defecation. IBS is divided into several subtypes including:

- Diarrhoea predominant (IBS-D)
- Constipation predominant (IBS-C)
- Alternating (IBS-A)
- Pain predominant.

These subtypes are identified by the dominant symptoms that the patient experiences.

This report provides the current prevalent population for Irritable Bowel Syndrome across 12 Major Markets (USA, Canada, France, Germany, Russia, Italy, Spain, UK, Brazil, Japan, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Irritable Bowel Syndrome have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Irritable Bowel Syndrome include:

• Abdominal pain
• Abdominal cramping
• Bloated/Gassy feeling
• Gas (Flatulence)
• Diarrhoea
• Constipation
• Mucus in stools

Reasons to Buy

• Able to quantify patient populations in global Irritable Bowel Syndrome market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Irritable Bowel Syndrome and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Irritable Bowel Syndrome prevalent population.
• Identify sub-populations within Irritable Bowel Syndrome which require treatment.
• Gain an understanding of the specific markets that have the largest number of Irritable Bowel Syndrome patients.

Key Topics Covered:

1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key comorbid conditions/Features associated with the disease
8. Methodology for quantification of patient numbers
9. Top-line prevalence for Irritable Bowel Syndrome
10. Features of Irritable Bowel Syndrome patients
11. Abbreviations used in the report
12. Patient-Based Offering
13. Online Pricing Data and Platforms
14. References
15. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/cqzpvf/irritable_bowel

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Gastroenterology